A review of tasquinimod in the treatment of advanced prostate cancer

Williamson, Stuart C.; Hartley, A.; Heer, Rakesh

doi:10.2147/dddt.s31500

Cited by 11 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tasquinimod is an experimental quinoline-3-carboxamide drug that has been studied in human prostate cancer (104). It has been shown to slow tumor growth in murine cancer models and to reduce MDSC tumor infiltration (105).…”

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 99%

“…It has been shown to slow tumor growth in murine cancer models and to reduce MDSC tumor infiltration (105). It is believed to act by binding to and inhibiting the activity of the S100A9 protein; S100A9 together with S100A8 are known to modulate myeloid cell activity though TLR4 binding (104,106). Because of its anti-MDSC properties, tasquinimod has been tested in murine TB models, and it has been shown not only to deplete MDSCs but also to decrease the relative bacterial burden in both lungs and spleens of infected animals (39).…”

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 99%

See 1 more Smart Citation

Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis

2021

View full text Add to dashboard Cite

Following infection with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), most human hosts are able to contain the infection and avoid progression to active TB disease through expression of a balanced, homeostatic immune response. Proinflammatory mechanisms aiming to kill, slow and sequester the pathogen are key to a successful host response. However, an excessive or inappropriate pro-inflammatory response may lead to granuloma enlargement and tissue damage, which may prolong the TB treatment duration and permanently diminish the lung function of TB survivors. The host also expresses certain anti-inflammatory mediators which may play either beneficial or detrimental roles depending on the timing of their deployment. The balance between the timing and expression levels of pro- and anti-inflammatory responses plays an important role in the fate of infection. Interestingly, M. tuberculosis appears to manipulate both sides of the human immune response to remodel the host environment for its own benefit. Consequently, therapies which modulate either end of this spectrum of immune responses at the appropriate time may have the potential to improve the treatment of TB or to reduce the formation of permanent lung damage after microbiological cure. Here, we highlight host-directed TB therapies targeting pro- or anti-inflammatory processes that have been evaluated in pre-clinical models. The repurposing of already available drugs known to modulate these responses may improve the future of TB therapy.

show abstract

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 99%

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 99%

Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis

2021

View full text Add to dashboard Cite

show abstract

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

et al. 2016

View full text Add to dashboard Cite

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms

Bezzi

Seitzer

Ishikawa

et al. 2018

Nat Med

143

117

View full text Add to dashboard Cite

Multiple immune-cell types can infiltrate tumors and promote progression and metastasis through different mechanisms, including immunosuppression. How distinct genetic alterations in tumors affect the composition of the immune landscape is currently unclear. Here, we characterized the immune-cell composition of prostate cancers driven by the loss of the critical tumor suppressor gene Pten, either alone or in combination with the loss of Trp53, Zbtb7a or Pml. We observed a striking quantitative and qualitative heterogeneity that was directly dependent on the specific genetic events in the tumor and ranged from 'cold', noninflamed tumors to massively infiltrated landscapes-results with important therapeutic implications. Further, we showed these qualitative differences in transcriptomic analysis of human prostate cancer samples. These data suggest that patient stratification on the basis of integrated genotypic-immunophenotypic analyses may be necessary for successful clinical trials and tailored precision immunological therapies.

show abstract

A review of tasquinimod in the treatment of advanced prostate cancer

Cited by 11 publications

References 61 publications

Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis

Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms

Contact Info

Product

Resources

About